Vaginal Diseases: Clinical Trials

84 trials for Vaginal Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 completed, 11 unknown, 7 terminated, 6 recruiting. 84 Phase 1, 20 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 184Completed 48, Unknown 11, Terminated 7, Recruiting 6, Active not recruiting 4, Withdrawn 4, Not yet recruiting 3, Suspended 1
Phase 220Completed 7, Terminated 3, Unknown 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Suspended 1, Withdrawn 1

Follow Vaginal Diseases: new trials by email Literature Review of Vaginal Diseases trials Research Report on Vaginal Diseases

Trials (filtered) newest first · largest first

All 84 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment
metronidazole (MTZ)+ LCFA-01 placebo + LC103 placebo, metronidazole (MTZ)+ LCFA-01 + LC103 placebo, metronidazole (MTZ)+ LC103 + LCFA-01 placebo - Bacterial Vaginosis
Phase 1Not yet recruitingMassachusetts General Hospital2802027-02-032026-10-15
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label
Phase 1RecruitingChangchun GeneScience Pharmaceutical Co., Ltd.422026-08-152026-10-15
A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women
GenSci142, Placebo GenSci142 - Bacterial Vaginosis
Phase 1Not yet recruitingChangchun GeneScience Pharmaceutical Co., Ltd.302025-12-012025-12-24
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
Phase 1 / Phase 2RecruitingChristian Hinrichs152025-08-112026-10-28
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma
Phase 1Active not recruitingJonsson Comprehensive Cancer Center302025-08-012026-10-20
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingSCG Cell Therapy Pte. Ltd.662024-10-012024-07-17
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis
Phase 1 / Phase 2UnknownNEXBIOME THERAPEUTICS1652024-07-082024-06-12
A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis
BNT331, Placebo - Bacterial Vaginosis
Phase 1CompletedBioNTech SE1022024-07-012026-10-05
Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers
CanProFem-AK - Candidosis Vaginal
Phase 1CompletedIndustrial Microbiology LLP202024-06-012024-08-02
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
INCB099280, axitinib - Advanced Solid Tumors
Phase 1 / Phase 2TerminatedIncyte Corporation52024-04-162026-06-04
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
Vaccine - Recurrent Vulvovaginal Candidiasis
Phase 1 / Phase 2Active not recruitingLimmaTech Biologics AG2512023-12-062026-03-04
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
HRYZ-T101 Injection, Fludarabine + Cyclophosphamide - Cervical Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1RecruitingHRYZ Biotech Co.322023-11-012024-02-02
Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens
Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest), Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin), Suppositoria for vaginal microflora recovery (Giynoflor) - Bacterial Vaginosis
Phase 1Active not recruitingDanylo Halytsky Lviv National Medical University2002023-09-012024-09-27
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
SCG142 TCR-T cells - Human Papillomavirus Associated Carcinomas, Cervical Cancer
Phase 1RecruitingThe Affiliated Hospital of Qingdao University182023-08-022024-08-09
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection
Phase 1CompletedScynexis, Inc.52023-07-122025-08-08
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell - Cervical Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1UnknownHRYZ Biotech Co.172023-03-212024-02-02
Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women
Experimental: Low dose LABTHERA-001 capsule, Experimental: Medium dose LABTHERA-001 capsule, Experimental: High dose LABTHERA-001 capsule - Bacterial Vaginosis, Vaginal Disease
Phase 1UnknownAtoGen Co. Ltd242022-11-022023-03-09
First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories
Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories - Colpomycosis, Bacterial Vaginosis
Phase 1UnknownProtelight Pharmaceuticals Australia PTY LTD502022-08-012023-12-11
Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)
Cervicovaginal secretions, Metronidazole gel, Screening tests - Bacterial Vaginosis
Phase 1WithdrawnJohns Hopkins University2022-03-012021-11-03
Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis
Conjugated Estrogens vaginal cream 0,625mg, platelet rich plasma - Atrophic Vaginitis, Postmenopausal Atrophic Vaginitis
Phase 1UnknownFayoum University1002021-11-132023-05-01

Showing 20 of 84. Sign in to see all of them.

Narrower conditions

Uterine Cervical Neoplasms (38)  ·  Vaginal Neoplasms (38)  ·  Vulvar Neoplasms (25)  ·  Vaginosis, Bacterial (23)  ·  Endometrial Neoplasms (20)  ·  Anus Neoplasms (16)  ·  Carcinoma, Ovarian Epithelial (14)  ·  Penile Neoplasms (14)  ·  Fallopian Tube Neoplasms (13)  ·  Urinary Bladder Neoplasms (11)  ·  Candidiasis, Vulvovaginal (10)  ·  Prostatic Neoplasms (10)  ·  Carcinoma, Hepatocellular (9)  ·  Colonic Neoplasms (9)  ·  Neoplasms (9)

Broader conditions

Female Urogenital Diseases and Pregnancy Complications (84)  ·  Genital Diseases (84)  ·  Urogenital Diseases (84)  ·  Female Urogenital Diseases (83)  ·  Genital Diseases, Female (83)  ·  Neoplasms by Site (39)  ·  Uterine Diseases (39)  ·  Infections (38)  ·  Urogenital Neoplasms (38)  ·  Uterine Cervical Diseases (38)  ·  Genital Neoplasms, Female (37)  ·  Vulvar Diseases (35)  ·  Uterine Neoplasms (34)  ·  Vaginitis (34)

Interventions

Metronidazole (6)  ·  Radiotherapy (5)  ·  Cyclophosphamide (4)  ·  fludarabine (4)  ·  Brachytherapy (3)  ·  Capecitabine (2)  ·  Cisplatin (2)  ·  Control Groups (2)  ·  Estriol (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Radiation (2)  ·  Radiosurgery (2)  ·  Topotecan (2)  ·  Trastuzumab (2)  ·  Vaccines (2)

Sponsors

National Cancer Institute (NCI) (6)  ·  M.D. Anderson Cancer Center (3)  ·  Case Comprehensive Cancer Center (2)  ·  Changchun GeneScience Pharmaceutical Co., Ltd. (2)  ·  HRYZ Biotech Co. (2)  ·  Regeneron Pharmaceuticals (2)  ·  The University of Texas Medical Branch, Galveston (2)  ·  University of Chicago (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Ain Shams University (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Anthony Lembo (1)  ·  AtoGen Co. Ltd (1)  ·  Beijing Health Guard Biotechnology, Inc (1)  ·  BioNTech SE (1)

Countries

United States (42)  ·  China (9)  ·  Canada (5)  ·  Australia (3)  ·  Belgium (3)  ·  Egypt (2)  ·  Germany (2)  ·  Israel (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Brazil (1)  ·  France (1)  ·  Japan (1)  ·  Kazakhstan (1)  ·  Kenya (1)

Top investigators

Jian Zhang, Doctor (2)  ·  Lilie L Lin (2)  ·  William P. Tew, MD (2)  ·  Ahinoam Lev-Sagie (1)  ·  Alan Bocking, MD, FRCSC (1)  ·  Amy L Lightner (1)  ·  Amy Lightner, MD (1)  ·  Ann H Klopp (1)  ·  Anthony Fyles, MD (1)  ·  Anthony W. Tolcher, MD (1)  ·  Ashwin Chatwani, MD (1)  ·  Charles Erlichman, MD (1)

Results publications

PMID 19949018, PMID 22002018, PMID 19238149, PMID 20068553, PMID 20179219, PMID 20347480, PMID 24718774, PMID 25427450, PMID 26223323, PMID 27093291, PMID 27412883, PMID 28363809, PMID 29697768, PMID 39836666, PMID 40273550, PMID 41291715

NIH funding

2023 (2), P30CA043703 (2), 2014 (1), P30CA016087 (1), P30CA016672 (1), U01CA062502 (1), U01CA076576 (1), U01CA076642 (1), UM1CA186644 (1)